Gil Beyen, Erytech CEO
October 25, 2021 09:10 AM EDT
R&D

A transat­lantic biotech flags a painful PhI­II can­cer flop, wav­ing a white flag

John Carroll

Editor & Founder

More than 4 years af­ter lit­tle Ery­tech in­flat­ed some rare pas­sion for its stock with up­beat Phase IIb da­ta for their lead drug in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times